Nalmefene oral - Lundbeck A/S
Alternative Names: CPH-101; JF-1; Lu AA36143; Nalmetrene; NIH-10365; ORF-11676; Selincro; SoberalLatest Information Update: 05 Nov 2023
At a glance
- Originator Rockefeller University; University of Miami
- Developer Lundbeck A/S; Otsuka Pharmaceutical; Somaxon Pharmaceuticals
- Class Anti-inflammatories; Opioid analgesics
- Mechanism of Action Opioid receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Alcoholism
- Discontinued Gambling; Interstitial cystitis; Pruritus; Rheumatoid arthritis; Shock; Smoking withdrawal